Clinical Observation of Baricitinib in the Treatment of 10 Cases of Refractory Adult-Onset Still's Disease
Abstract：Adult-onset Still's disease (AOSD) is a rare, idiopathic systemic autoimmune inflammatory disease, mainly characterized by fever, rash, arthritis or arthralgia, sore throat, hepatosplenomegaly and lymphadenopathy, increased total white blood cell count and neutrophil ratio, and even life-threatening complications such as macrophage activation syndrome and fulminant hepatitis [1].
Keywords：refractory adult-onset Still's diseaseJanus Kinase inhibitorsbaricitinib
Publication Date：2025-09-01
Online Publishing Date：2025-10-21(First online date of this platform, not the publication date of the document)
Pages：4( 781-784 )